25 research outputs found
A nitric oxide-donor pravastatin hybrid drug exerts antiplatelet and antiatherogenic activity in mice
Aim of the present study was to compare the lipid-lowering, antithrombotic and antiatherogenic properties of NCX-6550, nitropravastatin, a nitric-oxide donating derivative of pravastatin, with those of pravastatin in hypercholesterolemic mice. LDL receptor-deficient mice (LDLRâ/â) on a normal diet (ND) showed enhanced cholesterol levels as compared to wild type (WT) mice (6.8±1.2 mmol/L and 2.8±0.82 mmol/L, respectively). High fat diet (HFD) induced a large enhancement of cholesterolemia in LDLRâ/â mice (23.7±5.7 mmol/L, p<0.0001 vs LDLRâ/â ND and WT mice. Treatment with NCX 6550 (48 mg/kg), but not with equimolar pravastatin, reduced cholesterol in LDLRâ/âHFD. Platelet adhesion to collagen under high shear rate (3000 secâ1) was significantly higher in LDLRâ/â than in normal mice, and further enhanced in LDLRâ/âHFD (-27%, p<0.0001 vs untreated). NCX 6550 (48 mg/kg), but not pravastatin, reduced platelet adhesion, especially in LDLRâ/âHFD. U46619-induced platelet aggregation ex vivo was also inhibited by NCX 6550 (48 mg/kg) but not by the parent compound. Finally, photochemically-induced acute (1 hr) femoral artery thrombosis and delayed (21 days) intimal thickening was assessed. Thrombus size was larger in LDLRâ/â on HFD than in normocholesterolemic mice (0.46±0.04 vs 0.18±0.08 mg) and it was reduced by NCX 6550 (48 mg/kg) (0.08±0.02 mg, p<0.0001), but not by pravastatin (0.4±0.01 mg p=NS). Intimal thickening was greater in hypercholesterolemic than in normal mice (I/M normal=0.53±0.16, LDLRâ/â=1.1±0.15, LDLRâ/âHFD=1.75 ±0.25). Both NCX 6550 and pravastatin reduced intimal thickening in normal (-95% and -74.5%, respectively) and LDLRâ/â mice (-98% and -91%), while in strongly hyperlipidemic animals (LDLRâ/âHFD) NCX 6550 was more effective than pravastatin (-98% vs -65%, p<0.0001). NCX 6550 shows greater antithrombotic and antiatherogenic activity than pravastatin in highly hypercholesterolemic mice
Biomarkers of nanomaterials hazard from multi-layer data
Nanomaterials have a range of potential applications, however, toxicity remains a concern, limiting application and requiring extensive testing. Here, the authors report on a predictive framework made using a range of tests linking materials properties with toxicity, allowing the prediction of toxicity from physiochemical and biological properties.There is an urgent need to apply effective, data-driven approaches to reliably predict engineered nanomaterial (ENM) toxicity. Here we introduce a predictive computational framework based on the molecular and phenotypic effects of a large panel of ENMs across multiple in vitro and in vivo models. Our methodology allows for the grouping of ENMs based on multi-omics approaches combined with robust toxicity tests. Importantly, we identify mRNA-based toxicity markers and extensively replicate them in multiple independent datasets. We find that models based on combinations of omics-derived features and material intrinsic properties display significantly improved predictive accuracy as compared to physicochemical properties alone.Peer reviewe
The non-xanthine heterocyclic compound SCH 58261 is a new potent and selective A2a adenosine receptor antagonist
We have characterized the in vitro pharmacological profile of the new potent and selective A2a adenosine receptor antagonist SCH 58261 [7-(2-phenylethyl)-5-amino-2-(2-furyl)-pyrazolo-[4,3-e]-1,2, 4-triazolo[1,5-c]pyrimidine]. In binding studies on rat and bovine brain tissues, SCH 58261 showed affinity in the low nanomolar range at A2a adenosine striatal receptors and good A2a adenosine vs. A1 adenosine selectivity (about 50- to 100-fold in rat and bovine brain, respectively). SCH 58261 did not show affinity for either the A3 adenosine receptor or other receptors at concentrations up to 1 microM. Saturation experiments on rat A1 and A2a adenosine receptors indicated the competitive nature of the antagonism. SCH 58261 antagonized competitively the effects induced by the A2a adenosine-selective agonist CGS 21680 (2-[4-(2-carboxyethyl)-phenethyl-amino]-5'-N- ethylcarboxamidoadenosine) in two functional assays, such as inhibition of rabbit platelet aggregation and porcine coronary artery relaxation. Specifically, the compound showed pA2 values of 7.9 and 9.5, respectively. SCH 58261 (300 nM) failed to antagonize 5'-N-ethylcarboxamidoadenosine-induced vasorelaxation in the isolated guinea pig aorta, a response mediated by A2b adenosine receptors. Likewise, at the same concentration, the compound weakly inhibited the A1 adenosine-mediated negative chronotropic effect induced by 2-chloro-N6-cyclopentyladenosine in the isolated rat atria. These data show that SCH 58261 is a potent and selective non-xanthine A2a adenosine antagonist which has competitive properties in biological responses mediated by this receptor subtype. The compound is of interest for investigating the biological role of A2a adenosine receptors and deserves further attention to clarify the therapeutic potential of A2a antagonists
Nitric oxide prevents atorvastatin-induced skeletal muscle dysfunction and alterations in mice
Introduction:
Myopathy is the most common side effect of statins. Since nitric oxide (NO) has a key role in regulating skeletal muscle function, we studied whether the NO-donating atorvastatin NCX 6560 could show a better profile on skeletal muscle function and structure compared to atorvastatin.
Methods:
C57BL/6 mice received atorvastatin 40 mg/kg/day or an equivalent dose of NCX 6560 for 2 months. Muscle function was assessed treadmill test, serum creatine kinase (CK) activity, citrate synthase (CS) activity, and muscle histology.
Results:
Atorvastatin significantly (P<0.001) reduced muscle endurance, increased serum CK 6-fold, and induced muscle fiber atrophy. Conversely, NCX 6560 preserved muscle function, prevented CK increase and did not modify muscle structure. Interestingly, atorvastatin reduced CS activity, a marker for mitochondrial function, in gastrocnemius, diaphragm and heart, whereas NCX 6560 prevented such decrease.
Conclusion:
These findings suggest that NO may prevent statin-induced myopathy
Nitric oxide-releasing aspirin derivative, NCX 4016, promotes reparative angiogenesis and prevents apoptosis and oxidative stress in a mouse model of peripheral ischemia
BackgroundâRecently, nitric oxide (NO) donors have been developed that mimic the physiological intracellular release
of NO. We evaluated whether one of these new compounds, consisting of aspirin coupled to an NO-releasing moiety
(NCX 4016), would protect limbs from supervening arterial occlusion.
Methods and ResultsâMice were assigned to receive regular chow or chow containing NCX 4016 or aspirin (both at
300 ÎŒmol/kg body weight, daily) throughout the 3-week experimental period. One week after randomization, they
underwent surgical excision of the left femoral artery. Limb blood flow recovery (laser Doppler flowmetry) was
accelerated by NCX 4016 as compared with aspirin or vehicle (P<0.05). In controls, histological analysis revealed a
35% increase in the capillary density of ischemic muscles compared with contralateral ones, indicative of spontaneous
angiogenesis. Neovascularization was enhanced by NCX 4016 (91%; P<0.05 versus vehicle), but not by aspirin (51%;
P=NS versus vehicle). Furthermore, NCX 4016 reduced endothelial cell (EC) apoptosis (4.3±1.0 versus 8.7±2.0 in
aspirin and 12.6±3.3 ECs/1000 cap in vehicle; P<0.05 for either comparison) as well as caspase-3 mRNA levels in
ischemic muscles ([caspase-3/GAPDH]*100 =0.09±0.04 versus 2.30±0.44 in aspirin and 2.30±0.32 in vehicle;
P< 0.01 for either comparison). Nitrite levels and the ratio of reduced to oxidized glutathione were selectively increased
in ischemic muscles by NCX 4016. Vascular endothelial growth factor-A expression was reduced by aspirin, with this
effect being blunted by NCX 4016.
ConclusionsâPretreatment with the new oral NO-releasing aspirin derivative stimulates reparative angiogenesis and
prevents apoptosis and oxidative stress, thereby alleviating the consequences of supervening arterial occlusion
A2A-adenosine receptor reserve for coronary vasodilation
denosine is a potent coronary vasodilator and causes an increase of coronary blood flow by activation of A2A-adenosine receptors (A2A-AdoRs). The purpose of this study was to test the hypothesis that the high potency of adenosine and adenosine analogues to cause coronary vasodilation is explained by the presence of a large A2A-AdoR reserve (âspare receptorsâ)